Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Where
Chengdu
Age
18 years to 75 years
People
80
Run by
Sichuan University
See details and how to joinNCT06769971
No phaseTaking people
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
Where
Xi'an
Age
18 years to 75 years
People
60
Run by
Tang-Du Hospital
See details and how to joinNCT06644066
No phaseTaking people
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
Where
Shenyang
Age
18 years and over
People
38
Run by
Yunpeng Liu
See details and how to joinNCT06480864
Phase 2Taking people
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
60
Run by
Peng Zhang
See details and how to joinNCT06755684
Phase 3Enrolling by invitation
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
Where
Beijing
Age
18 months and over
People
350
Run by
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
See details and how to joinNCT06759857
No phaseTaking people
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
Where
Shanghai
Age
18 years to 75 years
People
40
Run by
Ruijin Hospital
See details and how to joinNCT06756217
Phase 2Not yet taking people in China
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
Where
Beijing
Age
18 years to 75 years
People
316
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06752408
Phase 2Taking people
Liposomal Irinotecan and Apatinib in ES-SCLC
Where
Hangzhou
Age
18 years to 75 years
People
30
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06749691
Phase 2Taking people
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Where
Shanghai
Age
18 years and over
People
58
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06749860
Phase 2Taking people
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Where
Shanghai
Age
18 years and over
People
22
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06749886
Early phase 1Enrolling by invitation
INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
Where
Weifang
Age
18 years to 75 years
People
10
Run by
Guangzhou Ruixin Biotechnological Co., LTD
See details and how to joinNCT06747832
Phase 2Taking people
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Where
Chengdu
Age
18 years to 70 years
People
20
Run by
Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT06532591
No phaseTaking people
Lymph Node Pathologic Grading Strategy
Where
Shanghai
People
2,998
Run by
Fudan University
See details and how to joinNCT06745830
No phaseTaking people
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
Where
Kunming
Age
18 years to 75 years
People
195
Run by
Yunnan Cancer Hospital
See details and how to joinNCT06742021
No phaseTaking people
New Method to Differentiate Benign and Malignant Pulmonary Nodules.
Where
Beijing
Age
18 years and over
People
150
Run by
China-Japan Friendship Hospital
See details and how to joinNCT06056999
No phaseNot yet taking people in China
The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
Where
Beijing
Age
18 years to 90 years
People
1,040
Run by
China-Japan Friendship Hospital
See details and how to joinNCT06739421
Phase 2Taking people
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Where
Guangzhou
Age
18 years to 70 years
People
120
Run by
Guangzhou Institute of Respiratory Disease
See details and how to joinNCT06739928
Phase 1/2Taking people
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Where
Beijing
Age
18 years to 75 years
People
78
Run by
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
See details and how to joinNCT06440057
Phase 2Taking people
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Where
Beijing
Age
18 years to 75 years
People
35
Run by
Beijing Chest Hospital, Capital Medical University
See details and how to joinNCT06467617
Phase 3Not yet taking people in China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Where
Tianjin
Age
18 years to 75 years
People
430
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06704620
Phase 2Taking people
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
25
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT06734182
Phase 3Taking people
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Where
Guangzhou
Age
18 years and over
People
516
Run by
Shanghai JMT-Bio Inc.
See details and how to joinNCT06735391
Early phase 1Not yet taking people in China
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
40
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT06735508
Phase 3Taking people
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Where
Jilin City
Age
18 years and over
People
180
Run by
Luye Pharma Group Ltd.
See details and how to joinNCT06496048
No phaseEnrolling by invitation
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
Where
Wuhan
Age
18 years to 80 years
People
1,000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06647836